cellTranspl.ru - The dependence of mesenchymal stem cells proliferation on some characteristics of donors

The dependence of mesenchymal stem cells proliferation on some characteristics of donors

HTML,

PDF, Volume IV, №2, 2009

Grigorian A.S., Kruglyakov P.V., Taminkina U.A., Polyntsev D.G.

Trans-Technologies Ltd., Saint-Petersburg, Russia

Keywords:
multipotent mesenchymal stromal cells, proliferation, cryopreservation, donor characteristics, CD71

Рейтинг: 0.00 Оцените статью: 1 2 3 4 5 Просмотров: 208, комментариев: 0

The application of multipotent mesenchymal stromal cells (MMSC), derived from the bone marrow, is an effective therapeutic method to treat various pathologies, including hematologic malignancies. MMSC clinical application requires their in vitro expansion to obtain the necessary amount of cells, and the cultivation period is limited to six passages. However, concerning the properties of this cell type, e.g. their proliferation activity, there are still a lot of different opinions. In our work we have investigated the dependence of the proliferative activity of MMSC from the third to seventh passage after cryopreservation, which are commonly used in clinics, on donor gender and age, and also on the percent of CD71+ cells in bone marrow aspirates and MMSC cultures. We have found that the proliferation of MMSC has no correlations with the above mentioned factors. The pure populations of MMSC is possible to obtain from donors of 18 to 70 years old.

1. Dominici М., Le Blanc К., Mueller I. et al. Minimal criteria for defining multipotent mesenchymal stem cells: The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8: 315-7.
2. Deans R.J., Moseley A.B. Mesenchymal stem cells: biology and potential clinical use. Exp. Hematol. 2000: 28: 875-84.
3. Barry F.P, Murphy J.M. Mesenchymal stem cells: clinical applications and biological characterization. Int. J. Biochem. Cell. Biol. 2004; 36: 568-84.
4. Jorgensen C, Gordeladze J., Noel D. Tissue engineering through autologous mesenchymal stem cells. Curr. Opin. Biotechnol. 2004; 15: 406-10.
5. Кос O.N., Gerson S.L., Cooper B.M. et al. Rapid hematopoietic recovery after co-infusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-doe chemotherapy. J. Clin. Oncol. 2000; 18: 207-16.
6. Lazarus H.H., Кос O.N., Devine S.M. et al. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients, Biol. Blood Marrow Transpl. 2005; 11: 389-98.
7. 7. Le Blanc K., Rasmusson I., Sundberg B. et al. Treatment of severe graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004; 363: 1439-41.
8. von Bonin M., Stujzel F., Goedecke A. et al. Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium. Bone Marrow Transplant. 2009; 43(3): 245-51.
9. Rodriguez R., Menendez P. Mesenchymal stem cells and their use as cell replacement therapy and disease modelling tool. J. Cell. Mol. Med. 2008; 12(6B): 2552-65
10. Horwitz E.M., Prockop D.J., Fitzpatrick L.A. et al. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat. Med. 1999; 5: 309-13.
11. Puontos I., Jones E., Tzioupis С et al. Growing bone and cartilage. Role of mesenchymal stem cells. J. Bone Joint Surg. Br. 2006; 88: 421-6.
12. Quarto R., Mastrogiacomo M., Cancedda R. et al. Repair of large bone defects with the use of autologous bone marrow stromal cells. N. Eng. J. Med. 2001; 344: 385-6.
13. Wepkina E.A., Kruglyakov P.V., Solomin L.N. i dr. Transplantaciya autogennyh mul'tipotentnyh mezenhimal'nyh stromal'nyh kletok na demineralizovannom kostnom matrikse pri pechenii lozhnyh sustavov dlinnyh trubchatyh kostej. Kletochnaya transplantologiya i tkanevaya inzheneriya 2007; 2(3): 67-74.
14. Caplan A.I. The mesengenic process. Clin. Plast. Surg. 1994; 21: 429-35.
15. Prockop D.J. Marrow stromal cells as a stem cells from nonhematopoietic tissues. Science 1997; 276: 71-4.
16. PittengerM.F., MackayA.M., Beck S.С etal. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284: 143-7
17. Bianco P., Gehron Robey P. Marrow stromal stem cells. J. Clin. Invest. 2000; 105: 1663-8
18. Bernardo M.E., Zaffaroni N., Novara F. Human bone marrow-derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms. Cancer Res. 2007; 67(19]; 9142-9
19. 19.Stenderup K., Justesen J., Clausen C, Kassem M. Aging is associated with decreased maximal life span and accelerated senescence of bone marrow stromal cells. Bone 2003; 33(6): 919-26.
20. Colter D.C., Class R., DiGirolamo СМ., Prockop D.J. Rapid expansion of recycling stem cells in cultures of plastic-adherent cells from human bone marrow. Proc. Natl. Acad. Sci. USA 2000; 97(7): 3213-8.
21. 21.Bonab M.M., Alimoghaddam K., Talebian F. et al. Aging of mesenchymal stem cell in vitro. BMC Cell Biology 2006; 7: 14.
22. Wagner W., Horn P., Castoldi M. et al. Replicative senescence of mesenchymal stem cells: a continuous and organized process. PLoS ONE 2008; 3(5): e2213.
23. Haack-Sorensen M., Bindslev L., Mortensen S. et al. The influence of freezing and storage on the characteristics and functions of human mesenchymal stromal cells isolated for clinical use. Cytotherapy 2007; 9(4): 328-37.
24. Kotobuki N., Hirose M., Machida H. et al. Viability and osteogenic potential of cryopreserved human bone marrow-derived mesenchymal cells. Tissue Eng. 2005; 11(5-6): 663-73.
25. Cristofalo V.J., Allen R.G., Pignolo R.J. et al. Relationship between donor age and the replicative lifespan of human cells in culture: a reevaluation. Proc. Natl. Acad. Sci. USA 1998; 95: 10614-19.
26. Mareschi K., Ferrero I., Rustichelli D. et al. Expansion of mesenchymal stem cells isolated from pediatric and adult donor bone marrow. J. Cell. Biochem. 2006; 97: 744-54.
27. Crisostomo P.R., Markel Т.Д., Wang M. et al. In the adult mesenchymal stem cell population, source gender is a biologically relevant aspect of protective power. Surgery 2007; 142(2): 215-21.
28. BabusHkov6 0., Prachar J., Kusenda J., Hraska V. Flow cytometric analysis of some activation/proliferation markers on human thymocytes and their correlation with cell proliferation. Neoplasma 1999; 46: 349-55.
29. Zhao Z.G., Liang Y., Li K. et al. Phenotypic and functional comparison of mesenchymal stem cells derived from the bone marrow of normal adults and patients with hematologic malignant diseases. Stem Cells Dev. 2007; 16(4): 637-48.
30. PittengerM.F., MackayA.M., Beck S.С etal. Multilineage potential of adult human mesenchymal stem cells.Science. 1999; 284: 143-7.
31. 31.Muraglia A., Cancedda R., Quarto R. Clonal mesenchymal progenitors from human bone marrow differentiate in vitro according to a hierarchical model. J. Cell. Sci. 2000; 113: 1161-6.
32. Kretlow J.D., Jin Y-Q., Liu W. et al. Donor age and cell passage affects differentiation of murine bone marrow-derived stem cells. BMC Cell Biology 2008; 9:60.
33. Tokalov S.V., Gruener S., Schindler S. et al. Age-related changes in the frequency of mesenchymal stem cells in the bone marrow of rats. Stem Cells Dev. 2007; 16(3): 439-46.
34. Zhang H., Fazel S., Tian H. et al. Increasing donor age adversely impacts beneficial effects of bone marrow but not smooth muscle myocardial cell therapy. Am. J. Heart. Circ. Physiol. 2005; 289: H2089-96
35. Stolzing A., Jones E., McGonagle D., Scutt A. Age-related changes in human bone marrow-derived mesenchymal stem cells: consequences for cell therapies. Mech. Ageing Dev. 2008; 129(3): 163-73.
36. Zhang L., Li P.P., Feng X. et al. Sex-related differences in neuronal cell survival and signaling in rats. Neurosci. Let. 2003; 337(2): 65-8.